Market News AIOpen the app

IDEAYA Biosciences picked IDE101 to develop as a treatment for certain solid tumors.

TrialRead the original at prnewswire.com
Good for IDYA

IDEAYA added IDE101 as a possible treatment for tumors with CDKN2A deficiency, creating a new path for drug development. Studies before human testing are underway, and a filing is planned for 2027, so patient benefit remains unproven.

IDYA · IDEAYA Biosciences

AI read · Good for IDYA

The AI's read

This gives IDEAYA another possible treatment program to study alone or with other drugs. The target is found in about 10% to 15% of solid tumors, including about 70% of pancreatic ductal adenocarcinoma. But studies are still underway before testing in people, and the filing is planned for 2027, so patient benefit remains unproven.

Get alerts for IDYA

Follow IDEAYA Biosciences (IDYA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IDYA
Free on the App Store and Google Play, or on the web.